Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1189 results
May 2019
-
Press Release
Novartis phase II data for new inhaled combination treatment (QVM149) demonstrates significant improvements over current standard-of-care inhaled treatment
New inhaled combination for asthma treatment (indacaterol acetate, glycopyrronium bromide and mometasone furoate - IND/GLY/MF) was superior to the standard of care (long-acting beta-agonist/inhaled… -
Press Release
Novartis data at ASCO and EHA demonstrate novel approaches to reimagining medicine in cancer and serious blood disorders
Overall survival results from MONALEESA-7 with Kisqali® (ribociclib)* plus endocrine therapy in premenopausal women with HR+/HER2- advanced breast cancer, to be presented at ASCO Primary… -
Press Release
Novartis data at AAN show Gilenya® is the first and only disease-modifying therapy with proven superiority versus glatiramer acetate in relapsing remitting MS
Full results from the ASSESS study demonstrate patients with relapsing remitting multiple sclerosis (RRMS) taking Gilenya® (fingolimod) 0.5mg had significantly fewer relapses than patients… -
Press Release
Sandoz demonstrates strategic focus on China, with first-of-a-kind generic approval under Quality Consistency Evaluation system
Sandoz receives generic approval for Rosuvastatin from China's National Medical Products Administration (NMPA) under Quality Consistency Evaluation (QCE) system Generic approval under China's… -
Ad-hoc Release
Novartis to acquire Xiidra®, expanding front-of-eye portfolio and strengthening leadership in eye care
Xiidra (lifitegrast ophthalmic solution) 5% fits strategically within industry-leading USD 4.6 billion Novartis ophthalmic pharmaceutical portfolio, laying groundwork for front-of-the-eye pipeline… -
Press Release
Novartis data at AAN show Mayzent's® positive impact on cognitive processing speed, a core element of cognitive function, in people living with secondary progressive MS
Data from EXPAND - the largest randomized controlled trial in a representative secondary progressive MS (SPMS) population - show Mayzent® (siponimod) had a meaningful benefit on cognitive… -
Press Release
New AveXis data at AAN showed long-term durability of Zolgensma® in patients with spinal muscular atrophy (SMA) Type 1
Interim long-term follow-up data showed all enrolled Cohort 2 patients maintained motor function and milestones achieved during the Phase 1 START trial Mean age of follow-up since dosing… -
Press Release
Novartis presents first-of-its-kind algorithm-based tool to help MS patients and physicians evaluate and discuss early signs of progression to secondary progressive MS
Up to 80% of relapsing remitting MS (RRMS) patients transition to secondary progressive MS (SPMS)[1], a stage of the disease leading to continuous functional decline, which is often undiagnosed or… -
Press Release
AveXis presented robust data at AAN demonstrating efficacy of Zolgensma® in broad spectrum of spinal muscular atrophy (SMA) patients
Interim data reported for the first time from STRONG in SMA Type 2 showed rapid motor function gains and milestone achievements with intrathecal Zolgensma (onasemnogene abeparvovec-xioi; AVXS-101… -
Press Release
Novartis to highlight extensive long-term safety and efficacy data of Aimovig® across the spectrum of migraine at AAN
After long-term Aimovig (erenumab) treatment, two-thirds of chronic migraine patients converted to episodic migraine, experiencing 11 fewer migraine days per month on average Separate study…
April 2019
-
Press Release
New data at AAN reinforce Novartis commitment to transforming the lives of people of all ages who live with neurological conditions
Novartis leads the way at AAN with 52 abstracts, showcasing its broad portfolio of transformative medicines and innovative solutions for people living with spinal muscular atrophy (SMA), multiple… -
Press Release
Sandoz enters agreement for proposed trastuzumab biosimilar, currently in Phase III development, to treat selected HER2-positive cancer tumors
Collaboration covers proposed trastuzumab biosimilar in Phase III development for human epidermal growth factor receptor 2 positive (HER2+) breast and gastric tumors Per licence agreement,…